Does the media prefer NKTR or PRGO?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Nektar Therapeutics and 2 mentions for Perrigo. Nektar Therapeutics' average media sentiment score of 0.51 beat Perrigo's score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OMER or NKTR more profitable?

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Nektar Therapeutics -284.18% -85.40% -39.99%

Does the media favor OMER or NKTR?

In the previous week, Omeros had 10 more articles in the media than Nektar Therapeutics. MarketBeat recorded 13 mentions for Omeros and 3 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.51 beat Omeros' score of 0.40 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NKTR or ASMB?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 3 mentions for Nektar Therapeutics and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.77 beat Nektar Therapeutics' score of 0.51 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Nektar Therapeutics (NKTR) Competitors

$67.12 +2.28 (+3.52%)

As of 12:36 PM Eastern

Compare

NKTR vs. SUPN, PRGO, PCRX, OMER, and ASMB

Should you buy Nektar Therapeutics stock or one of its competitors? MarketBeat compares Nektar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nektar Therapeutics include Supernus Pharmaceuticals (SUPN), Perrigo (PRGO), Pacira BioSciences (PCRX), Omeros (OMER), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceuticals" industry.

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Nektar Therapeutics (NASDAQ:NKTR) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Supernus Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	41.07	-$164.08M	-$8.42	N/A
Supernus Pharmaceuticals	$718.95M	3.85	-$38.55M	-$0.51	N/A

Nektar Therapeutics presently has a consensus price target of $149.63, suggesting a potential upside of 122.91%. Supernus Pharmaceuticals has a consensus price target of $62.83, suggesting a potential upside of 31.89%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Nektar Therapeutics had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 3 mentions for Nektar Therapeutics and 0 mentions for Supernus Pharmaceuticals. Nektar Therapeutics' average media sentiment score of 0.51 beat Supernus Pharmaceuticals' score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nektar Therapeutics	Positive
Supernus Pharmaceuticals	Neutral

Nektar Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Supernus Pharmaceuticals has a net margin of -3.74% compared to Nektar Therapeutics' net margin of -284.18%. Supernus Pharmaceuticals' return on equity of 13.07% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

75.9% of Nektar Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Nektar Therapeutics beats Supernus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Perrigo?

Nektar Therapeutics (NASDAQ:NKTR) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Nektar Therapeutics currently has a consensus target price of $149.63, suggesting a potential upside of 122.91%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 85.81%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Nektar Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nektar Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Nektar Therapeutics has higher earnings, but lower revenue than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	41.07	-$164.08M	-$8.42	N/A
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Perrigo	-43.50%	9.96%	3.90%

In the previous week, Nektar Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 3 mentions for Nektar Therapeutics and 2 mentions for Perrigo. Nektar Therapeutics' average media sentiment score of 0.51 beat Perrigo's score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nektar Therapeutics beats Perrigo on 10 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Pacira BioSciences has a net margin of 0.70% compared to Nektar Therapeutics' net margin of -284.18%. Pacira BioSciences' return on equity of 10.24% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.38	$7.03M	$0.12	211.75
Nektar Therapeutics	$55.23M	41.07	-$164.08M	-$8.42	N/A

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Nektar Therapeutics had 3 more articles in the media than Pacira BioSciences. MarketBeat recorded 3 mentions for Nektar Therapeutics and 0 mentions for Pacira BioSciences. Nektar Therapeutics' average media sentiment score of 0.51 beat Pacira BioSciences' score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pacira BioSciences	Neutral
Nektar Therapeutics	Positive

Pacira BioSciences currently has a consensus price target of $29.40, indicating a potential upside of 15.70%. Nektar Therapeutics has a consensus price target of $149.63, indicating a potential upside of 122.91%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Pacira BioSciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Summary

Pacira BioSciences beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Omeros has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$0.70	13.69
Nektar Therapeutics	$55.23M	41.07	-$164.08M	-$8.42	N/A

In the previous week, Omeros had 10 more articles in the media than Nektar Therapeutics. MarketBeat recorded 13 mentions for Omeros and 3 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.51 beat Omeros' score of 0.40 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Omeros currently has a consensus price target of $38.00, indicating a potential upside of 296.54%. Nektar Therapeutics has a consensus price target of $149.63, indicating a potential upside of 122.91%. Given Omeros' higher possible upside, research analysts clearly believe Omeros is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

48.8% of Omeros shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Summary

Omeros beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Assembly Biosciences?

Nektar Therapeutics (NASDAQ:NKTR) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Assembly Biosciences has higher revenue and earnings than Nektar Therapeutics. Assembly Biosciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	41.07	-$164.08M	-$8.42	N/A
Assembly Biosciences	$72.30M	5.73	-$6.12M	-$0.11	N/A

Nektar Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Nektar Therapeutics presently has a consensus target price of $149.63, indicating a potential upside of 122.91%. Assembly Biosciences has a consensus target price of $44.00, indicating a potential upside of 68.78%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Nektar Therapeutics is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Assembly Biosciences has a net margin of -8.98% compared to Nektar Therapeutics' net margin of -284.18%. Assembly Biosciences' return on equity of -4.21% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

In the previous week, Nektar Therapeutics had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 3 mentions for Nektar Therapeutics and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 1.77 beat Nektar Therapeutics' score of 0.51 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assembly Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Nektar Therapeutics and Assembly Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTR vs. The Competition

Export

Metric	Nektar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.27B	$3.07B	$6.80B	$12.42B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-7.97	20.38	27.05	24.17
Price / Sales	41.07	344.36	517.90	92.83
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	15.22	4.26	10.65	6.23
Net Income	-$164.08M	$65.94M	$3.59B	$331.42M
7 Day Performance	-0.07%	-1.49%	-0.84%	-1.22%
1 Month Performance	10.07%	0.16%	1.42%	-1.36%
1 Year Performance	170.77%	17.24%	24.75%	18.43%

Nektar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
NKTR Nektar Therapeutics	2.5285 of 5 stars	$67.12 +3.5%	$149.63 +122.9%	+160.0%	$2.27B	$55.23M	N/A	220
SUPN Supernus Pharmaceuticals	3.1356 of 5 stars	$47.73 +2.3%	$62.83 +31.6%	+46.6%	$2.77B	$718.95M	N/A	580
PRGO Perrigo	3.1764 of 5 stars	$10.15 +2.5%	$19.33 +90.6%	-60.7%	$1.40B	$4.25B	N/A	8,100
PCRX Pacira BioSciences	1.7466 of 5 stars	$25.33 +1.3%	$29.40 +16.1%	+17.4%	$996.69M	$734.86M	211.10	720
OMER Omeros	3.8368 of 5 stars	$10.37 -1.2%	$38.00 +266.4%	+186.6%	$750.58M	N/A	14.81	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nektar Therapeutics (NKTR) Competitors

NKTR vs. SUPN, PRGO, PCRX, OMER, and ASMB

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Nektar Therapeutics compare to Perrigo?

Summary

How does Nektar Therapeutics compare to Pacira BioSciences?

Summary

How does Nektar Therapeutics compare to Omeros?

Summary

How does Nektar Therapeutics compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nektar Therapeutics (NKTR) Competitors

NKTR vs. SUPN, PRGO, PCRX, OMER, and ASMB

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Which has preferable earnings and valuation, NKTR or SUPN?

Do analysts recommend NKTR or SUPN?

Does the media favor NKTR or SUPN?

Which has more volatility and risk, NKTR or SUPN?

Is NKTR or SUPN more profitable?

Do insiders and institutionals have more ownership in NKTR or SUPN?

Summary

How does Nektar Therapeutics compare to Perrigo?

Do analysts recommend NKTR or PRGO?

Which has more volatility & risk, NKTR or PRGO?

Which has stronger earnings & valuation, NKTR or PRGO?

Is NKTR or PRGO more profitable?

Does the media prefer NKTR or PRGO?

Do insiders & institutionals hold more shares of NKTR or PRGO?

Summary

How does Nektar Therapeutics compare to Pacira BioSciences?

Is PCRX or NKTR more profitable?

Which has preferable earnings & valuation, PCRX or NKTR?

Do insiders & institutionals have more ownership in PCRX or NKTR?

Does the media refer more to PCRX or NKTR?

Do analysts rate PCRX or NKTR?

Which has more volatility and risk, PCRX or NKTR?

Summary

How does Nektar Therapeutics compare to Omeros?

Which has better earnings & valuation, OMER or NKTR?

Does the media favor OMER or NKTR?

Which has more volatility and risk, OMER or NKTR?

Do analysts prefer OMER or NKTR?

Do institutionals & insiders believe in OMER or NKTR?

Is OMER or NKTR more profitable?

Summary

How does Nektar Therapeutics compare to Assembly Biosciences?

Which has better valuation and earnings, NKTR or ASMB?

Which has more volatility & risk, NKTR or ASMB?

Do analysts rate NKTR or ASMB?

Do insiders and institutionals have more ownership in NKTR or ASMB?

Is NKTR or ASMB more profitable?

Does the media prefer NKTR or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools